![]() | ![]() |
Formats:
|
||||
Copyright © 2002, BMJ Clinical networks
Advantages include flexibility, strength, speed, and focus on
clinical issues NHS Confederation, London SW1E 5ER (Email: Nigel.edwards/at/nhsconfed.co.uk) This article has been cited by other articles in PMC.The NHS seems fond of structural solutions to its
problems, even though experience suggests that reorganisation is a
distraction, fails to solve the problems it was supposed to address,
and creates new ones. Seasoned NHS observers might therefore be
sceptical of the growing interest in clinical networks. There are
certainly reasons for caution but clinical networks do seem to offer
several important advantages to patients and clinicians. The Scottish Office defines managed clinical networks as “linked
groups of health professionals and organisations from primary,
secondary, and tertiary care working in a co-ordinated manner,
unconstrained by existing professional and [organisational]
boundaries to ensure equitable provision of high quality effective
services.” Their report contrasted these with loose networks and
suggests that they differ from hub and spoke models in that the
interests of the network would dominate those of individual
hospitals.1,2 These networks may be grouped by function
(for example, pathology, emergency medicine, critical care) or client
group (children), disease (cancer, renal) or specialty (vascular
surgery). Network organisations have several theoretical advantages in terms of
their flexibility, robustness, and ability to respond quickly to a
rapidly changing environment.3 Formal NHS networks have
started to emerge as a way of sustaining vulnerable services and
maintaining access where the requirements of training or
subspecialisation would otherwise mean complete closure of local
services. A network may avoid the need to withdraw clinicians who form
important parts of other services—for example, overcoming the problem
of how to maintain emergency general services when vascular surgery is
centralised. Networks offer a way of making the best use of scarce specialist
expertise, standardising care, improving access, and reducing any
“distance-decay” effects that can result from the concentration of
specialist services in large centres. They can create systems that
ensure patients receive a standard investigation and are referred on
rather than being held in a local service that may not have the full
range of expertise. As a result, networks should be able to exploit any
relationships between quality and volume and enable a faster spread of
innovation. This appears to have been an important reason for the
growth of networks in cancer and coronary heart disease. The cancer networks have started to report significant benefits as a
result of being able to focus on the needs of their patients without
the distraction of managing the less patient focused parts of the
system such as non-clinical support services. In critical care,
networks have been used to increase efficiency and responsiveness by
combining scarce resources to iron out the effect of variations in
demand. Networks may stimulate creativity and innovation by providing increased
opportunities for interaction of people from different disciplines and
organisations. Because of their flexibility they can also create an
environment that allows self organisation, development and
learning—features which seem to be related to improved outcomes and
staff retention. Large networks are more likely to cover the large
populations needed to support the different disciplines and expertise
required for research and training in an increasingly competitive
global market.4,5 A real attraction of networks is that they focus on clinical
issues and create organic and flexible organisations that can respond
well to a changing environment. This and their collaborative nature
seem to appeal to many clinicians. These positive features, however,
that can put them directly at odds with the organisations in which
their members sit. Who decides about a consultant appointment, drug
formulary, or operational policy—the trust or the network? Who should
be accountable for the clinical governance of network members? In fact
pragmatic answers can be found, but many networks will have some
difficult encounters over these and other issues and will need strong
clinical and managerial leadership to deal with them. A more hazardous possibility is that networks will be seen as the next
structural panacea and turned into new NHS organisations. For some
services there may be significant advantages from shifting the
managerial focus away from institutions and towards services for
patients. But this could destroy the creativity and fleetness of foot
that networks can develop. The idea of putting all services into
networks is also starting to emerge. If this helps to build better
relationships and improve the flow of information the results could be
beneficial. If it is simply a structural change it could create a model
very similar to that adopted for the privatised railways, with the
attending problems of competing priorities, a lack of connection
between the parts, and confusion about responsibilities. Networks need to explore and develop but we need to avoid a rush to
manage risks and worries about accountability by forcing them into
being just another part of the NHS hierarchy. They will however, have
to start to think about how they will talk to the public, commission
services from other providers, measure their performance, and come to
terms with some of the formality of the NHS without losing their spark. Footnotes The NHS Confederation received an educational grant from
Roche for work on developing policy on clinical networks.References 1. The Scottish Office; Department of Health. Acute services review report. Leeds: NHS Executive; 1998. 2. The Scottish Office; Department of Health. Introduction of managed Clinical Networks within the NHS in Scotland. Leeds: NHS Executive; 1999. 3. Edwards N, Fraser SW. Clinical networks: A discussion paper. London: NHS Confederation; 2001. 4. Blumenthal D, Edwards N. A tale of two systems: the changing academic health center. Health Aff. 2000;19:86–101. 5. Smith R. UK is losing market share in pharmaceutical research. BMJ. 2000;321:1041. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||
BMJ. 2000 Oct 28; 321(7268):1041.
[BMJ. 2000]